RIOT

#1115
Riot Platforms, Inc. - Common Stock
18.6 4 USD
+0.05%
Market Price
Sektor: Finanzen
Basis: USD
Gewinnwährung: USD
Tagesspanne
18.64
18.64
Jahresspanne
11.50
30.32
Tagesänderung
+4.78%
Monatliche Änderung
-12.20%
6 month change
+18.88%
Jahresänderung
+39.73%
Vorheriger Schlusskurs
17.7 9
Open
18.6 4
Tief
18.6 4
Hoch
18.6 4
Volumen
211
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Riot Platforms, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Riot Platforms, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Riot Platforms, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Riot Platforms, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Riot Platforms, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Riot Platforms, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Riot Platforms, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Riot Platforms, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Riot Platforms, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Riot Platforms, Inc. current report, Q1 FY2026
8-K

Riot Platforms, Inc. current report, Q1 FY2017

Full document

SEC Filing Summary: Bioptix, Inc. (Form 8-K)

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Bioptix, Inc. (formerly Venaxis, Inc.) on January 6, 2017. The filing reports a significant change in the composition of the Company's Board of Directors. Note: The request metadata referenced "Riot Platforms, Inc.," but the provided filing text explicitly identifies the registrant as Bioptix, Inc.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.

Material Changes

The primary material change reported is the restructuring of the Board of Directors:

  • Resignations: Gail S. Schoettler, Susan A. Evans, and David E. Welch resigned from the Board of Directors.
  • Appointments: John O'Rourke and Mike Dai were appointed as directors.
  • Committee Assignments:
    • John O'Rourke (Audit Committee Financial Expert) was appointed Chairman of the Audit Committee.
    • Mike Dai was appointed Chairman of the Compensation Committee.
    • Jeffrey G. Beeghley was appointed Chairman of the Nominating and Governance Committee.
    • All other directors were removed from these committees.
  • Reason for Resignation: Resigning directors affirmed their departure was not related to any disagreement or concerns regarding the Company's financial status or financial statements.

Outlook, Risks, and Management Commentary

The filing provides biographical details for the new directors:

  • John O'Rourke: Managing Member of ATG Capital LLC; former CFO of Fidelity Property Group; holds degrees in Accounting and Finance.
  • Mike Dai: Associate with ALOE Finance Inc.; former roles at Grant Thornton LLP; currently CFO and director of Santa Maria Petroleum Inc.

No specific guidance, forward-looking financial outlook, or new risk factors were disclosed in this filing.

Key Facts for Investor Verification

  • Verify the independence status of the newly appointed directors under NASDAQ Rule 5605(a)(2).
  • Confirm the effective date of the resignations and appointments (January 6, 2017).
  • Review the attached Exhibit 99.1 (Letter of Resignation) for any additional context not summarized in the main text.
  • Clarify the discrepancy between the request metadata (Riot Platforms) and the filing content (Bioptix, Inc.).

Nachrichten